• 1
    Mittag M, Beckheinrich P, Haustein F. Systemic sclerosis-related Raynaud's phenomenon: effects of ilioprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001; 81: 2947.
  • 2
    Andersen GN, Caidahl K, Elsadig K, Patersson AS, Waldenström A, Minchevar N, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis. Arthritis Rheum 2000; 43: 108593.
  • 3
    Denton CP, Bickerstaff MCM, Shiven X, Carulli MT, Haskard DO. Serial circulating adhesion molecule levels reflecting disease severity in systemic sclerosis. Br J Rheumatol 1995; 34: 104854.
  • 4
    Takahashi H, Ho S, Hanano M, Wada K, Niwano H, Seki Y, et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behaviour with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 41: 329.
  • 5
    Shinichi O, Takado S, Miyake S. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular disease. Am J Clin Pathol 1994; 101: 10913.
  • 6
    White B, Moore W, Wigley F, Hui Q. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 94754.
  • 7
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 8
    Rodnan GP, Lipinski E, Lucksick J. Skin thickness and collagen contents in progressive systemic sclerosis (scleroderma) and localized scleroderma. Arthritis Rheum 1979; 22: 13040.
  • 9
    Steen V, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 75967.
  • 10
    Hebbar M, Lassale P, Janina van Hee D, Bisiau S. E-selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis. Arthritis Rheum 1995; 38: 40612.
  • 11
    Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000; 43: 108593.
  • 12
    Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998; 91: 5616.
  • 13
    Mercie P, Seigneur M, Constans J, Boisseau M, Conri C. [Assay of plasma thrombomodulin in systemic diseases]. Rev Med Interne 1997; 18: 12631.
  • 14
    Salojin KV, Le Tonqueze M, Saraux A, Nassonov EL, Dueymes M, Piette JC, et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997; 102: 17885.
  • 15
    Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995; 287: 43942.
  • 16
    Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 55: 1227.
  • 17
    Mizutani H, Hayashi T, Nouchi N, Inachi S, Suzuki K, Shimizu M. Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. Acta Med Okayama 1996; 50: 2937.
  • 18
    Stratton RJ, Pompon L, Coghlan JG, Pearson JD, Black CM. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 2000; 59: 1324.
  • 19
    Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. J Rheumatol 1993; 20: 14445.
  • 20
    Trifiletti A, Bartolone S, Scamardi R, Pizzoleo MA, Sottilotta G, Larosa D, et al. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon. Panminerva Med 2000; 42: 79.
  • 21
    Mercie P, Seigneur M, Conri C. Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J Rheumatol 1995; 22: 14401.
  • 22
    Candela M, Pansoni A, Jannino L, Menditto VG, Natalini M, Ravaglia F, et al. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine. Ann Ital Med Int 2001; 16: 1704.
  • 23
    Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro: induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996; 97: 1119.
  • 24
    Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998; 114: 293300.
  • 25
    Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma): relationship to platelet and endothelial cell activation. J Rheumatol 2002; 29: 256570.
  • 26
    Gruschwitz MS, Hornstein OP, von Den DP. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 1849.
  • 27
    Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ. VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol 1996; 135: 67886.
  • 28
    Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998; 37: 118892.
  • 29
    Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993; 20: 80914.
  • 30
    Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 1998; 15: 3429.
  • 31
    Ertenli I, Kiraz S, Erturk H, Haznedaroglu IC, Celik I, Calguneri M, et al. Circulating thrombopoietin in systemic sclerosis. J Rheumatol 1999; 26: 193941.
  • 32
    Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116: 17480.
  • 33
    Weyl A, Vanscheidt W, Weiss JM, Peschen M, Schopf E, Simon J. Expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin and their ligands VLA-4 and LFA-1 in chronic venous leg ulcers. J Am Acad Dermatol 1996; 34: 41823.
  • 34
    Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of β1 and β2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992; 35: 2908.
  • 35
    Haznedaroglu IC, Ozdemir O, Ozcebe O, Dundar SV, Kirazli S. Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease. Thromb Haemost 1996; 75: 9745.
  • 36
    Kiraz S, Ertenli I, Benekli M, Haznedaroglu IC, Calguneri M, Celik I, et al. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999; 8: 73741.
  • 37
    Ippoliti G, Miori L, Negri M, Rovati B, Lorenzutti F, Zerbinati N, et al. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. Transplant Proc 1994; 26: 31178.
  • 38
    Mouthon L, Agard C. Treating systemic sclerosis in 2001. Joint Bone Spine 2001; 68: 393402.
  • 39
    Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 83844.
  • 40
    Akesson A, Scheja A, Lundin A, Wolheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 72935.
  • 41
    Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of the oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003. In press.
  • 42
    Steen VD, Lanz JK, Conte C. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994; 34: 12906.